
Academic Journal
Q2Multiple Sclerosis Journal – Experimental, Translational and Clinical
About Multiple Sclerosis Journal – Experimental, Translational and Clinical
Multiple Sclerosis Journal - Experimental, Translational and Clinical is a scholarly journal published by SAGE Publications Inc.. SCImago 2025 lists it in Q2, with an SJR of 0.665 and H-index of 37.
Coverage: 2015-2026. Research categories: Neurology (clinical) (Q2); Cellular and Molecular Neuroscience (Q3).
Open-access policies and author information
Reported in the official DOAJ public CSV snapshot (2026-09-01), downloaded 2026-10-03. Record updated 2026-01-13. This snapshot does not establish today’s listing status or fee quotation.
Publisher policy links recorded by DOAJ
- Aims and scope ↗
- Editorial board ↗
- Instructions for authors ↗
- Peer-review policy ↗
- Publication fees ↗
- Fee waivers ↗
- Licence terms ↗
- Preservation policy ↗
Source: DOAJ journal record. Journal metadata is distributed by DOAJ under CC0. Confirm current fees, tax, eligibility and waiver terms with the publisher.
Source-backed journal facts
Topics in published research
Multiple Sclerosis Research Studies; Peripheral Neuropathies and Disorders; Amyotrophic Lateral Sclerosis Research; Polyomavirus and related diseases; Systemic Sclerosis and Related Diseases; Systemic Lupus Erythematosus Research.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Anti-CD20 associated enterovirus meningoencephalitis: A narrative review with two illustrative cases
Kedar R Mahajan, Frank Bittner, Mary Alissa Willis, Carlos Isada et al.
2026-07 · DOI: 10.1177/20552173261471722Predictors of high- versus low-intensity first-line multiple sclerosis treatments
Amanda V. Gusovsky Chevalier, Kyle Murray, Anna Lin, Kevin Kerber et al.
2026-07 · DOI: 10.1177/20552173261487868Ocular-motor conduction dynamics and variability in multiple sclerosis–related internuclear ophthalmoparesis: A randomized dalfampridine trial
Alessandro Serra, Clara Chisari, Jonathan B Jacobs, Margaret M Skelly et al.
2026-07 · DOI: 10.1177/20552173261464348Effectiveness of a digital health application ( levidex ) on quality of life in people with multiple sclerosis: A pragmatic, randomized controlled trial (LAMONT)
Björn Meyer, Gereon Nelles, Linda Betz, Arnfin Bergmann et al.
2026-07 · DOI: 10.1177/20552173261475519Feasibility of a registry-integrated eHealth program for managing fatigue and cognitive problems in multiple sclerosis
Päivi Hämäläinen, Hanna Kuusisto, Henriikka Nurmi, Sari Avikainen et al.
2026-07 · DOI: 10.1177/20552173261453202Walking fatigability indices correspond with perception of changes in gait speed and quality during an instrumented 6-minute walking test in people with multiple sclerosis
Felipe Balistieri Santinelli, Massimiliano Pau, Zuhal Abasiyanik, Deborah Severijns et al.
2026-07 · DOI: 10.1177/20552173261471715Establishing humoral immunity to rabies in a person with multiple sclerosis through booster vaccination: A case report
D Dinov, P Hardeman, J Tessier, PV Sguigna et al.
2026-07 · DOI: 10.1177/20552173261474744Cross-platform comparison of blood glial fibrillary acidic protein quantification in healthy controls and multiple sclerosis
Anne Ladwig, Antje Torge, Kim Kristin Falk, Antonia Dammann et al.
2026-07 · DOI: 10.1177/20552173261460155Real world observation of fatigue in multiple sclerosis comparing self-guided online cognitive behavioral therapy versus psychoeducation
Maria Protopapa, Jana Samarin, Muriel Schraad, Livia S Lang et al.
2026-07 · DOI: 10.1177/20552173261468118Insights from a Danish nationwide implementation of patient-reported outcomes in multiple sclerosis
Rolf Pringler Holm, Luigi Pontieri, Mie Reith Mahler, Hanna Joensen et al.
2026-07 · DOI: 10.1177/20552173261468115Retinal atrophy in multiple sclerosis is similar with extended versus standard interval natalizumab therapy
Brenna McCormack, Omar Ezzedin, Ting-Yi Lin, Anna Bacchetti et al.
2026-07 · DOI: 10.1177/20552173261475496Acute effects of high-dose corticosteroids on serum biomarker profiles in primary CNS demyelinating disease: A pilot study
Anastasia P Chumakova, Michael Demetriou, Michael Sy
2026-07 · DOI: 10.1177/20552173261487037Effect of ocrelizumab on rates of retinal atrophy in relapsing multiple sclerosis
Brenna McCormack, Anna Bacchetti, Ting-Yi Lin, Giulia S. Moretti et al.
2026-07 · DOI: 10.1177/20552173261478412Patterns and predictors of transition between multiple sclerosis phenotypes: A longitudinal analysis
Gauruv Bose, Nupur Greene, Brian C. Healy, Howard L. Weiner et al.
2026-07 · DOI: 10.1177/20552173261473717Circulating microRNA expression profiles as biomarkers of disease activity in multiple sclerosis
Ifat Vigiser, Yoav Zeevi, Yoav Piura, Hadar Kolb et al.
2026-07 · DOI: 10.1177/20552173261471723Sex-dependent bioactive lipid mediator profiles in multiple sclerosis
Wing Hee Fung, Serhii Chornyi, Menno M Schoonheim, Bernard MJ Uitdehaag et al.
2026-07 · DOI: 10.1177/20552173261475501Assessing the feasibility, theoretical interest, and observed behaviors of adding genetic data to a patient-reported multiple sclerosis registry
Kaarina Kowalec, Douglas Menendez, Gary Cutter, Robert J Fox et al.
2026-07 · DOI: 10.1177/20552173261467203Real-world adherence to and persistence with ofatumumab, infusion, oral, and other self-injectable disease-modifying therapies in patients with multiple sclerosis
Ming-Hui Tai, Brandon Brown, Riley Taiji, Ariane Faucher et al.
2026-07 · DOI: 10.1177/20552173261464369Establishing demographic-based normative values for neurofilament light chain and glial fibrillary acidic protein in serum and plasma samples
Tyler L Borko, Alanna Ritchie, Sean Selva, Stefan Sillau et al.
2026-07 · DOI: 10.1177/20552173261466440Family planning and multiple sclerosis – Part 1: Patient perspectives on treatment choices in Sweden
Alejandra Machado, Emma Pettersson, Fitsum Sebsibe Teni, Katharina Fink et al.
2026-07 · DOI: 10.1177/20552173261472661Reviews
Community Reviews
Version History
October 4, 2026 at 9:10 pm
October 2, 2026